Temozolomide (TMZ)
Also known as: TMZ
Chemotherapy agent used in glioblastoma. DELPHAI (preprint) models temozolomide responses in GBM organoids; temozolomide-specific single-cell perturbation data remain scarce. VC0129 · preprint
Review pending Version 0.1.0 · status: draft · last expert review: not yet reviewed
Relations
| Subject | Relation | Object | Confidence | Evidence (role) |
|---|---|---|---|---|
| Temozolomide | perturbs | Patient-derived GBM organoids | medium | VC0129 · preprint supports Preprint; organoid responses to temozolomide are modelled, not measured clinically. |
| DELPHAI | associated with | Temozolomide | medium | VC0129 · preprint supports Preprint; temozolomide responses modelled in GBM organoids. |
Appears in research topics
- AI virtual cell models (Models)
- Perturbation data for glioblastoma: radiotherapy, drugs and CRISPR (Perturbations)
- Therapy-induced plasticity in glioblastoma (Transitions)
Appears in library items (1)
Items whose title, tags or one-line summary match this entity (derived from the data), plus the items cited as evidence for the description.
- VC0129 · preprint DELPHAI, AI Agent for Predicting Drug Response and Resistance — Peng et al., preprint, 2025
For research and education only. Not medical advice and not a recommendation of any diagnosis, treatment or product. Patients should consult their own physicians.